



Clinical trial results:

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Summary

EudraCT number	2015-004024-54
Trial protocol	GB BE DE ES FR IT
Global end of trial date	02 July 2021

Results information

Result version number	v1 (current)
This version publication date	23 March 2022
First version publication date	23 March 2022

Trial information

Trial identification

Sponsor protocol code	GS-US-380-1489
-----------------------	----------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02607930
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Gilead Sciences
Sponsor organisation address	333 Lakeside Drive, Foster City, CA, United States, 94404
Public contact	Gilead Clinical Study Information Center, Gilead Sciences, GileadClinicalTrials@gilead.com
Scientific contact	Gilead Clinical Study Information Center, Gilead Sciences, GileadClinicalTrials@gilead.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	02 July 2021
Is this the analysis of the primary completion data?	Yes
Primary completion date	09 May 2017
Global end of trial reached?	Yes
Global end of trial date	02 July 2021
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective of this study was to evaluate the efficacy of a fixed dose combination (FDC) containing bicitgravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus a FDC containing abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) in human immunodeficiency virus type 1 (HIV-1) infected, antiretroviral treatment naive-adults.

Protection of trial subjects:

The protocol and consent/assent forms were submitted by each investigator to a duly constituted Independent Ethics Committee (IEC) or Institutional Review Board (IRB) for review and approval before study initiation. All revisions to the consent/assent forms (if applicable) after initial IEC/IRB approval were submitted by the investigator to the IEC/IRB for review and approval before implementation in accordance with regulatory requirements. This study was conducted in accordance with recognized international scientific and ethical standards, including but not limited to the International Conference on Harmonization guideline for Good Clinical Practice (ICH GCP) and the original principles embodied in the Declaration of Helsinki.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	13 November 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 6
Country: Number of subjects enrolled	Canada: 33
Country: Number of subjects enrolled	Dominican Republic: 3
Country: Number of subjects enrolled	France: 21
Country: Number of subjects enrolled	Germany: 13
Country: Number of subjects enrolled	Italy: 18
Country: Number of subjects enrolled	Spain: 43
Country: Number of subjects enrolled	United Kingdom: 31
Country: Number of subjects enrolled	United States: 463
Worldwide total number of subjects	631
EEA total number of subjects	101

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	627
From 65 to 84 years	4
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Participants were enrolled at study centers in Europe, Dominican Republic, and North America. The first participant was screened on 13 November 2015. The last study visit occurred on 02 July 2021.

Pre-assignment

Screening details:

739 participants were screened.

Period 1

Period 1 title	Double-Blinded Treatment Phase
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	B/F/TAF

Arm description:

Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) (50/200/25 mg) tablets fixed-dose combination (FDC) + abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) (ABC/DTG/3TC) placebo orally once daily for at least 144 weeks, without regard to food.

Arm type	Experimental
Investigational medicinal product name	ABC/DTG/3TC Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Administered once daily

Investigational medicinal product name	B/F/TAF
Investigational medicinal product code	
Other name	GS-9883/F/TAF
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

50/200/25 mg FDC administered once daily

Arm title	ABC/DTG/3TC
------------------	-------------

Arm description:

Abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) (600/50/300 mg) FDC tablet + B/F/TAF placebo orally once daily for 144 weeks, without regard to food.

Arm type	Active comparator
Investigational medicinal product name	B/F/TAF Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Administered once daily

Investigational medicinal product name	ABC/DTG/3TC
Investigational medicinal product code	
Other name	Triumeq®
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

600/50/300 mg FDC administered once daily

Number of subjects in period 1^[1]	B/F/TAF	ABC/DTG/3TC
Started	314	315
Completed	262	262
Not completed	52	53
Protocol violation	2	3
Death	2	1
Non-compliance with study drug	3	5
Adverse event	-	4
Lost to follow-up	25	19
Withdrew consent	14	18
Investigator's discretion	6	3

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: Two participants in B/F/TAF arm were randomized but was not treated.

Period 2

Period 2 title	Open-Label B/F/TAF Extension Phase
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	B/F/TAF to B/F/TAF

Arm description:

After Week 144, participants continued to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants were given the option to receive open-label (OL) B/F/TAF for 96 weeks. After the Week 96 OL Visit, participants in a country where B/F/TAF was not commercially available were given the option to continue OL B/F/TAF until the product became accessible through an access program or until Gilead elected to discontinue the study in that country, whichever occurred first.

Arm type	Experimental
Investigational medicinal product name	B/F/TAF
Investigational medicinal product code	
Other name	GS-9883/F/TAF
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

50/200/25 mg FDC administered once daily

Arm title	ABC/DTG/3TC to B/F/TAF
Arm description:	
After Week 144, participants continued to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants were given the option to receive OL B/F/TAF for 96 weeks. After the Week 96 OL Visit, participants in a country where B/F/TAF was not commercially available were given the option to continue OL B/F/TAF until the product became accessible through an access program or until Gilead elected to discontinue the study in that country, whichever occurred first.	
Arm type	Experimental
Investigational medicinal product name	B/F/TAF
Investigational medicinal product code	
Other name	GS-9883/F/TAF
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

50/200/25 mg FDC administered once daily

Number of subjects in period 2^[2]	B/F/TAF to B/F/TAF	ABC/DTG/3TC to B/F/TAF
Started	252	254
Completed	218	221
Not completed	34	33
Protocol violation	1	1
Death	-	1
Adverse event	4	2
Non-compliance with study drug	1	-
Lost to follow-up	15	10
Withdrew consent	10	13
Investigator's discretion	2	5
Lack of efficacy	1	1

Notes:

[2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: 10 participants from B/F/TAF arm did not enter the Open-Label Extension Phase.

8 participants from ABC/DTG/3TC arm did not enter the Open-Label Extension Phase.

Baseline characteristics

Reporting groups

Reporting group title	B/F/TAF
Reporting group description: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) (50/200/25 mg) tablets fixed-dose combination (FDC) + abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) (ABC/DTG/3TC) placebo orally once daily for at least 144 weeks, without regard to food.	
Reporting group title	ABC/DTG/3TC
Reporting group description: Abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) (600/50/300 mg) FDC tablet + B/F/TAF placebo orally once daily for 144 weeks, without regard to food.	

Reporting group values	B/F/TAF	ABC/DTG/3TC	Total
Number of subjects	314	315	629
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
arithmetic mean	34	34	
standard deviation	± 10.9	± 10.8	-
Gender categorical			
Units: Subjects			
Female	29	33	62
Male	285	282	567
Race			
Not Permitted = Local regulators did not allow collection of race.			
Units: Subjects			
American Indian or Alaska Native	2	4	6
Asian	6	10	16
Black	114	112	226
Native Hawaiian or Pacific Islander	1	2	3
White	180	179	359
Other	9	8	17
Not Permitted	2	0	2
Ethnicity			
Not Permitted = Local regulators did not allow collection of ethnicity.			
Units: Subjects			
Hispanic or Latino	72	65	137
Not Hispanic or Latino	240	249	489
Not Permitted	2	1	3
HIV-1 RNA Categories			
Units: Subjects			
≤ 100,000 copies/mL	261	265	526
> 100,000 ≤ 400,000 copies/mL	45	38	83
> 400,000 copies/mL	8	12	20
CD4 Cell Count Categories			
Units: Subjects			

< 50 Cells/ μ L	7	10	17
\geq 50 to < 200 Cells/ μ L	29	22	51
\geq 200 to < 350 Cells/ μ L	69	58	127
\geq 350 to < 500 Cells/ μ L	87	91	178
\geq 500 Cells/ μ L	122	134	256
HIV-1 RNA Units: log10 copies/mL median standard deviation	4.41 \pm 0.647	4.42 \pm 0.685	-
CD4 Cell Count Units: Cells/ μ L arithmetic mean standard deviation	453 \pm 220.8	476 \pm 231.4	-
Hip Bone Mineral Density (BMD)			
Measure Analysis Population Description: The Hip Dual-energy X-ray Absorptiometry (DXA) Analysis Set included all participants who were randomized into the study, received at least 1 dose of study drug, and had non-missing values for baseline hip BMD.			
Units: g/cm ² arithmetic mean standard deviation	1.048 \pm 0.1572	1.057 \pm 0.1520	-
Spine BMD			
Measure Analysis Population Description: The Spine DXA Analysis Set included all participants who were randomized into the study, received at least 1 dose of study drug, and had nonmissing values for baseline spine BMD.			
Units: g/cm ² arithmetic mean standard deviation	1.139 \pm 0.1847	1.142 \pm 0.1713	-

End points

End points reporting groups

Reporting group title	B/F/TAF
Reporting group description: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) (50/200/25 mg) tablets fixed-dose combination (FDC) + abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) (ABC/DTG/3TC) placebo orally once daily for at least 144 weeks, without regard to food.	
Reporting group title	ABC/DTG/3TC
Reporting group description: Abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) (600/50/300 mg) FDC tablet + B/F/TAF placebo orally once daily for 144 weeks, without regard to food.	
Reporting group title	B/F/TAF to B/F/TAF
Reporting group description: After Week 144, participants continued to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants were given the option to receive open-label (OL) B/F/TAF for 96 weeks. After the Week 96 OL Visit, participants in a country where B/F/TAF was not commercially available were given the option to continue OL B/F/TAF until the product became accessible through an access program or until Gilead elected to discontinue the study in that country, whichever occurred first.	
Reporting group title	ABC/DTG/3TC to B/F/TAF
Reporting group description: After Week 144, participants continued to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants were given the option to receive OL B/F/TAF for 96 weeks. After the Week 96 OL Visit, participants in a country where B/F/TAF was not commercially available were given the option to continue OL B/F/TAF until the product became accessible through an access program or until Gilead elected to discontinue the study in that country, whichever occurred first.	
Subject analysis set title	All B/F/TAF
Subject analysis set type	Full analysis
Subject analysis set description: Blinded Phase: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) (50/200/25 mg) tablets fixed-dose combination (FDC) + abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) (ABC/DTG/3TC) placebo orally once daily for at least 144 weeks, without regard to food. Open-Label Extension Phase: After Week 144, participants continued to take their blinded study drug and attended visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants were given the option to receive open-label (OL) B/F/TAF for 96 weeks. After the Week 96 OL Visit, participants in a country where B/F/TAF was not commercially available were given the option to continue OL B/F/TAF until the product became accessible through an access program or until Gilead elected to discontinue the study in that country, whichever occurred first.	

Primary: Percentage of Participants who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm

End point title	Percentage of Participants who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm
End point description: The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Full Analysis Set included all participants who were randomized into the study and received at least 1 dose of study drug.	
End point type	Primary
End point timeframe: Week 48	

End point values	B/F/TAF	ABC/DTG/3TC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	314	315		
Units: percentage of participants				
number (not applicable)	92.4	93.0		

Statistical analyses

Statistical analysis title	B/F/TAF, ABC/DTG/3TC
Statistical analysis description:	
Differences in percentages of participants between groups and their 95.002% CIs were calculated based on Mantel-Haenszel (MH) proportions adjusted by baseline HIV-1 RNA stratum ($\leq 100,000$ vs. $> 100,000$ copies/mL) and region stratum (US vs. Ex-US).	
Comparison groups	B/F/TAF v ABC/DTG/3TC
Number of subjects included in analysis	629
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[1]
Parameter estimate	Difference in Percentages
Point estimate	-0.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.8
upper limit	3.6

Notes:

[1] - A sample of approximately 600 participants randomized 1:1 achieves at least 95% power using a non-inferiority margin of 12% assuming a response rate in both groups of 91% (Reference Genvoya studies) and a one-sided alpha level of 0.025.

Statistical analysis title	B/F/TAF, ABC/DTG/3TC
Comparison groups	B/F/TAF v ABC/DTG/3TC
Number of subjects included in analysis	629
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.78 ^[2]
Method	Cochran-Mantel-Haenszel

Notes:

[2] - p-value was calculated from CMH test stratified by baseline HIV-1 RNA stratum ($\leq 100,000$ vs. $> 100,000$ copies/mL) and region stratum (US vs. Ex-US).

Secondary: Percentage of Participants who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm

End point title	Percentage of Participants who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm
-----------------	---

End point description:

The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at

the predefined time point within an allowed window of time, along with study drug discontinuation status. Participants in the Full Analysis Set were analyzed.

End point type	Secondary
End point timeframe:	
Week 96	

End point values	B/F/TAF	ABC/DTG/3TC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	314	315		
Units: percentage of participants				
number (not applicable)	87.9	89.8		

Statistical analyses

Statistical analysis title	B/F/TAF, ABC/DTG/3TC
Statistical analysis description:	
Differences in percentages of participants between groups and their 95% CIs were calculated based on Mantel-Haenszel (MH) proportions adjusted by baseline HIV-1 RNA stratum ($\leq 100,000$ vs. $> 100,000$ copies/mL) and region stratum (US vs. Ex-US).	
Comparison groups	B/F/TAF v ABC/DTG/3TC
Number of subjects included in analysis	629
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Difference in Percentages
Point estimate	-1.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.9
upper limit	3.1

Statistical analysis title	B/F/TAF, ABC/DTG/3TC
Comparison groups	B/F/TAF v ABC/DTG/3TC
Number of subjects included in analysis	629
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.45 ^[3]
Method	Cochran-Mantel-Haenszel

Notes:

[3] - p-value was calculated from CMH test stratified by baseline HIV-1 RNA stratum ($\leq 100,000$ vs. $> 100,000$ copies/mL) and region stratum (US vs. Ex-US).

Secondary: Percentage of Participants who Achieved HIV-1 RNA < 50 Copies/mL at Week 144 as Defined by the US FDA-Defined Snapshot Algorithm

End point title	Percentage of Participants who Achieved HIV-1 RNA < 50
-----------------	--

End point description:

The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 144 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Participants in the Full Analysis Set were analyzed.

End point type Secondary

End point timeframe:

Week 144

End point values	B/F/TAF	ABC/DTG/3TC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	314	315		
Units: percentage of participants				
number (not applicable)	81.5	84.1		

Statistical analyses

Statistical analysis title B/F/TAF, ABC/DTG/3TC

Statistical analysis description:

Differences in percentages of participants between groups and their 95% CIs were calculated based on MH proportions adjusted by baseline HIV-1 RNA stratum ($\leq 100,000$ vs. $> 100,000$ copies/mL) and region stratum (US vs. Ex-US).

Comparison groups	B/F/TAF v ABC/DTG/3TC
Number of subjects included in analysis	629
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Difference in Percentages
Point estimate	-2.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.5
upper limit	3.4

Statistical analysis title B/F/TAF, ABC/DTG/3TC

Comparison groups B/F/TAF v ABC/DTG/3TC

Number of subjects included in analysis 629

Analysis specification Pre-specified

Analysis type other

P-value = 0.39 ^[4]

Method Cochran-Mantel-Haenszel

Notes:

[4] - p-value was calculated from CMH test stratified by baseline HIV-1 RNA stratum ($\leq 100,000$ vs. $> 100,000$ copies/mL) and region stratum (US vs. Ex-US).

Secondary: Percentage of Participants who Achieved HIV-1 RNA < 20 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm

End point title	Percentage of Participants who Achieved HIV-1 RNA < 20 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm
-----------------	---

End point description:

The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Participants in the Full Analysis Set were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 48

End point values	B/F/TAF	ABC/DTG/3TC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	314	315		
Units: percentage of participants				
number (not applicable)	87.6	87.3		

Statistical analyses

Statistical analysis title	B/F/TAF, ABC/DTG/3TC
----------------------------	----------------------

Statistical analysis description:

The differences in percentages of participants between treatment groups and their 95% CIs were calculated based on the MH proportions adjusted by baseline HIV-1 RNA stratum ($\leq 100,000$ vs. $> 100,000$ copies/mL) and region stratum (US vs. Ex-US).

Comparison groups	B/F/TAF v ABC/DTG/3TC
Number of subjects included in analysis	629
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Difference in Percentages
Point estimate	0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.8
upper limit	5.6

Statistical analysis title	B/F/TAF, ABC/DTG/3TC
----------------------------	----------------------

Comparison groups	B/F/TAF v ABC/DTG/3TC
-------------------	-----------------------

Number of subjects included in analysis	629
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.87 ^[5]
Method	Cochran-Mantel-Haenszel

Notes:

[5] - p-value was calculated from CMH test stratified by baseline HIV-1 RNA stratum ($\leq 100,000$ vs. $> 100,000$ copies/mL) and region stratum (US vs. Ex-US).

Secondary: Percentage of Participants who Achieved HIV-1 RNA < 20 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm

End point title	Percentage of Participants who Achieved HIV-1 RNA < 20 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm
-----------------	---

End point description:

The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Participants in the Full Analysis Set were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 96

End point values	B/F/TAF	ABC/DTG/3TC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	314	315		
Units: percentage of participants				
number (not applicable)	83.4	84.8		

Statistical analyses

Statistical analysis title	B/F/TAF, ABC/DTG/3TC
Comparison groups	B/F/TAF v ABC/DTG/3TC
Number of subjects included in analysis	629
Analysis specification	Pre-specified
Analysis type	other ^[6]
Parameter estimate	Difference in Percentages
Point estimate	-1.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.9
upper limit	4.6

Notes:

[6] - The differences in percentages of participants between treatment groups and their 95% CIs were calculated based on the MH proportions adjusted by baseline HIV-1 RNA stratum ($\leq 100,000$ vs. $> 100,000$ copies/mL) and region stratum (US vs. Ex-US).

Statistical analysis title	B/F/TAF, ABC/DTG/3TC
----------------------------	----------------------

Comparison groups	B/F/TAF v ABC/DTG/3TC
Number of subjects included in analysis	629
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.69 [7]
Method	Cochran-Mantel-Haenszel

Notes:

[7] - p-value was calculated from CMH test stratified by baseline HIV-1 RNA stratum ($\leq 100,000$ vs. $> 100,000$ copies/mL) and region stratum (US vs. Ex-US).

Secondary: Percentage of Participants who Achieved HIV-1 RNA < 20 Copies/mL at Week 144 as Defined by the US FDA-Defined Snapshot Algorithm

End point title	Percentage of Participants who Achieved HIV-1 RNA < 20 Copies/mL at Week 144 as Defined by the US FDA-Defined Snapshot Algorithm
-----------------	--

End point description:

The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Week 144 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Participants in the Full Analysis Set were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 144

End point values	B/F/TAF	ABC/DTG/3TC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	314	315		
Units: percentage of participants				
number (not applicable)	78.0	82.2		

Statistical analyses

Statistical analysis title	B/F/TAF, ABC/DTG/3TC
----------------------------	----------------------

Statistical analysis description:

The differences in percentages of participants between treatment groups and their 95% CIs were calculated based on the MH proportions adjusted by baseline HIV-1 RNA stratum ($\leq 100,000$ vs. $> 100,000$ copies/mL) and region stratum (US vs. Ex-US).

Comparison groups	B/F/TAF v ABC/DTG/3TC
Number of subjects included in analysis	629
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Difference in Percentages
Point estimate	-4.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.5
upper limit	2.1

Statistical analysis title	B/F/TAF, ABC/DTG/3TC
Comparison groups	B/F/TAF v ABC/DTG/3TC
Number of subjects included in analysis	629
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.19 [8]
Method	Cochran-Mantel-Haenszel

Notes:

[8] - p-value was calculated from CMH test stratified by baseline HIV-1 RNA stratum ($\leq 100,000$ vs. $> 100,000$ copies/mL) and region stratum (US vs. Ex-US).

Secondary: Change from Baseline in log10 HIV-1 RNA at Week 48

End point title	Change from Baseline in log10 HIV-1 RNA at Week 48
End point description: Participants in the Full Analysis Set with available data were analyzed.	
End point type	Secondary
End point timeframe: Baseline, Week 48	

End point values	B/F/TAF	ABC/DTG/3TC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	295	302		
Units: log10 copies/mL				
arithmetic mean (standard deviation)	-3.11 (\pm 0.641)	-3.07 (\pm 0.738)		

Statistical analyses

Statistical analysis title	B/F/TAF, ABC/DTG/3TC
Statistical analysis description: Difference in least-squares mean (LSM), and its 95% confidence interval (CI) were adjusted by baseline HIV-1 RNA stratum and region stratum.	
Comparison groups	B/F/TAF v ABC/DTG/3TC
Number of subjects included in analysis	597
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.48 [9]
Method	ANOVA
Parameter estimate	Difference in LSM
Point estimate	-0.03

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.12
upper limit	0.06

Notes:

[9] - p-value was adjusted by baseline HIV-1 RNA stratum and region stratum.

Secondary: Change from Baseline in log10 HIV-1 RNA at Week 96

End point title	Change from Baseline in log10 HIV-1 RNA at Week 96
End point description: Participants in the Full Analysis Set with available data were analyzed.	
End point type	Secondary
End point timeframe: Baseline, Week 96	

End point values	B/F/TAF	ABC/DTG/3TC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	279	288		
Units: log10 copies/mL				
arithmetic mean (standard deviation)	-3.09 (± 0.643)	-3.10 (± 0.705)		

Statistical analyses

Statistical analysis title	B/F/TAF, ABC/DTG/3TC
Statistical analysis description: Difference in LSM, and its 95% CI were adjusted by baseline HIV-1 RNA stratum and region stratum.	
Comparison groups	B/F/TAF v ABC/DTG/3TC
Number of subjects included in analysis	567
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.99
Method	ANOVA
Parameter estimate	Difference in LSM
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.09
upper limit	0.09

Secondary: Change from Baseline in log10 HIV-1 RNA at Week 144

End point title	Change from Baseline in log10 HIV-1 RNA at Week 144
End point description: Participants in the Full Analysis Set with available data were analyzed.	
End point type	Secondary
End point timeframe: Baseline, Week 144	

End point values	B/F/TAF	ABC/DTG/3TC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	260	269		
Units: log10 copies/mL				
arithmetic mean (standard deviation)	-3.11 (± 0.639)	-3.10 (± 0.681)		

Statistical analyses

Statistical analysis title	B/F/TAF, ABC/DTG/3TC
Statistical analysis description: Difference in LSM, and its 95% CI were adjusted by baseline HIV-1 RNA stratum and region stratum.	
Comparison groups	B/F/TAF v ABC/DTG/3TC
Number of subjects included in analysis	529
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.88
Method	ANOVA
Parameter estimate	Difference in LSM
Point estimate	0.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.08
upper limit	0.1

Secondary: Change from Baseline in CD4+ Cell Count at Week 48

End point title	Change from Baseline in CD4+ Cell Count at Week 48
End point description: Participants in the Full Analysis Set with available data were analyzed.	
End point type	Secondary
End point timeframe: Baseline, Week 48	

End point values	B/F/TAF	ABC/DTG/3TC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	294	300		
Units: cells/ μ L				
arithmetic mean (standard deviation)	235 (\pm 185.8)	228 (\pm 188.7)		

Statistical analyses

Statistical analysis title	B/F/TAF, ABC/DTG/3TC
Statistical analysis description: Difference in LSM, and its 95% CI were adjusted by the baseline HIV-1 RNA and region stratum.	
Comparison groups	B/F/TAF v ABC/DTG/3TC
Number of subjects included in analysis	594
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.69 ^[10]
Method	ANOVA
Parameter estimate	Difference in LSM
Point estimate	6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-24
upper limit	36

Notes:

[10] - P-value was adjusted by the baseline HIV-1 RNA and region stratum.

Secondary: Change from Baseline in CD4+ Cell Count at Week 96

End point title	Change from Baseline in CD4+ Cell Count at Week 96
End point description: Participants in the Full Analysis Set with available data were analyzed.	
End point type	Secondary
End point timeframe: Baseline, Week 96	

End point values	B/F/TAF	ABC/DTG/3TC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	276	286		
Units: cells/ μ L				
arithmetic mean (standard deviation)	287 (\pm 206.9)	288 (\pm 246.8)		

Statistical analyses

Statistical analysis title	B/F/TAF, ABC/DTG/3TC
Statistical analysis description: Difference in LSM, and its 95% CI were adjusted by the baseline HIV-1 RNA and region stratum.	
Comparison groups	B/F/TAF v ABC/DTG/3TC
Number of subjects included in analysis	562
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.94 ^[11]
Method	ANOVA
Parameter estimate	Difference in LSM
Point estimate	-1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-39
upper limit	36

Notes:

[11] - P-value was adjusted by the baseline HIV-1 RNA and region stratum.

Secondary: Change from Baseline in CD4+ Cell Count at Week 144

End point title	Change from Baseline in CD4+ Cell Count at Week 144
End point description: Participants in the Full Analysis Set with available data were analyzed.	
End point type	Secondary
End point timeframe: Baseline, Week 144	

End point values	B/F/TAF	ABC/DTG/3TC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	255	260		
Units: cells/μL				
arithmetic mean (standard deviation)	299 (± 224.9)	317 (± 219.5)		

Statistical analyses

Statistical analysis title	B/F/TAF, ABC/DTG/3TC
Statistical analysis description: Difference in LSM, and its 95% CI were adjusted by baseline HIV-1 RNA stratum and region stratum.	
Comparison groups	B/F/TAF v ABC/DTG/3TC

Number of subjects included in analysis	515
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.3 ^[12]
Method	ANOVA
Parameter estimate	Difference in LSM
Point estimate	-20
Confidence interval	
level	95 %
sides	2-sided
lower limit	-59
upper limit	18

Notes:

[12] - p-value was adjusted by baseline HIV-1 RNA stratum and region stratum.

Secondary: Percentage Change from Baseline in Hip BMD at Week 48

End point title	Percentage Change from Baseline in Hip BMD at Week 48
End point description:	Participants in the Hip DXA Analysis Set with available data were analyzed.
End point type	Secondary
End point timeframe:	
Baseline, Week 48	

End point values	B/F/TAF	ABC/DTG/3TC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	278	281		
Units: percentage change				
arithmetic mean (standard deviation)	-0.802 (± 2.3280)	-1.148 (± 2.5126)		

Statistical analyses

Statistical analysis title	B/F/TAF, ABC/DTG/3TC
Comparison groups	B/F/TAF v ABC/DTG/3TC
Number of subjects included in analysis	559
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.092
Method	ANOVA
Parameter estimate	Difference in LSM
Point estimate	0.346
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.057
upper limit	0.748

Secondary: Percentage Change from Baseline in Hip BMD at Week 96

End point title	Percentage Change from Baseline in Hip BMD at Week 96
-----------------	---

End point description:

Participants in the Hip DXA Analysis Set with available data were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 96

End point values	B/F/TAF	ABC/DTG/3TC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	250	257		
Units: percentage change				
arithmetic mean (standard deviation)	-1.128 (± 2.7702)	-1.262 (± 2.8524)		

Statistical analyses

Statistical analysis title	B/F/TAF, ABC/DTG/3TC
Comparison groups	B/F/TAF v ABC/DTG/3TC
Number of subjects included in analysis	507
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.59
Method	ANOVA
Parameter estimate	Difference in LSM
Point estimate	0.135
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.356
upper limit	0.625

Secondary: Percentage Change from Baseline in Hip BMD at Week 144

End point title	Percentage Change from Baseline in Hip BMD at Week 144
-----------------	--

End point description:

Participants in the Hip DXA Analysis Set with available data were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 144

End point values	B/F/TAF	ABC/DTG/3TC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	236	240		
Units: percentage change				
arithmetic mean (standard deviation)	-1.020 (\pm 3.7638)	-1.291 (\pm 3.1140)		

Statistical analyses

Statistical analysis title	B/F/TAF, ABC/DTG/3TC
Comparison groups	B/F/TAF v ABC/DTG/3TC
Number of subjects included in analysis	476
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.39
Method	ANOVA
Parameter estimate	Difference in LSM
Point estimate	0.271
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.351
upper limit	0.893

Secondary: Percentage Change from Baseline in Spine BMD at Week 48

End point title	Percentage Change from Baseline in Spine BMD at Week 48
End point description:	Participants in the Spine DXA Analysis Set with available data were analyzed.
End point type	Secondary
End point timeframe:	
Baseline, Week 48	

End point values	B/F/TAF	ABC/DTG/3TC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	284	285		
Units: percentage change				
arithmetic mean (standard deviation)	-0.772 (\pm 3.2228)	-0.552 (\pm 3.0956)		

Statistical analyses

Statistical analysis title	B/F/TAF, ABC/DTG/3TC
Comparison groups	B/F/TAF v ABC/DTG/3TC
Number of subjects included in analysis	569
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.41
Method	ANOVA
Parameter estimate	Difference in LSM
Point estimate	-0.221
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.741
upper limit	0.3

Secondary: Percentage Change from Baseline in Spine BMD at Week 96

End point title	Percentage Change from Baseline in Spine BMD at Week 96
End point description:	Participants in the Spine DXA Analysis Set with available data were analyzed.
End point type	Secondary
End point timeframe:	
Baseline, Week 96	

End point values	B/F/TAF	ABC/DTG/3TC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	256	258		
Units: percentage change				
arithmetic mean (standard deviation)	-0.705 (± 3.8721)	-0.219 (± 3.5159)		

Statistical analyses

Statistical analysis title	B/F/TAF, ABC/DTG/3TC
Comparison groups	B/F/TAF v ABC/DTG/3TC

Number of subjects included in analysis	514
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.14
Method	ANOVA
Parameter estimate	Difference in LSM
Point estimate	-0.485
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.126
upper limit	0.155

Secondary: Percentage Change from Baseline in Spine BMD at Week 144

End point title	Percentage Change from Baseline in Spine BMD at Week 144
End point description:	Participants in the Spine DXA Analysis Set with available data were analyzed.
End point type	Secondary
End point timeframe:	
Baseline, Week 144	

End point values	B/F/TAF	ABC/DTG/3TC		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	243	244		
Units: percentage change				
arithmetic mean (standard deviation)	-0.371 (\pm 4.4369)	0.035 (\pm 3.5182)		

Statistical analyses

Statistical analysis title	B/F/TAF, ABC/DTG/3TC
Comparison groups	B/F/TAF v ABC/DTG/3TC
Number of subjects included in analysis	487
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.26
Method	ANOVA
Parameter estimate	Difference in LSM
Point estimate	-0.406
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.119
upper limit	0.307

Secondary: Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 Open-Label as Defined by Missing = Excluded algorithm

End point title	Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 Open-Label as Defined by Missing = Excluded algorithm
-----------------	---

End point description:

The percentage of participants with HIV-1 RNA < 50 copies/mL was analyzed using Missing = Excluded for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set. All missing data was excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation). The denominator for percentages at a visit was the number of participants in the all B/F/TAF analysis set with non-missing HIV-1 RNA value at that visit. Participants in All B/F/TAF Analysis Set (who were randomized into the randomized phase of the study and received at least 1 dose of the B/F/TAF in the randomized phase or at least 1 dose of the B/F/TAF in the open label extension phase) with available data were analyzed. For the B/F/TAF group, Week 48 open-label time point refers to Week 192; for Missing = Excluded analysis, it included the available participants at that time point from the Randomized Phase.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, open-label Week 48

End point values	ABC/DTG/3TC to B/F/TAF	All B/F/TAF		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	212	237		
Units: percentage of participants				
number (confidence interval 95%)	100 (98.3 to 100)	99.2 (97.0 to 99.9)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 Open-Label as Defined by Missing = Failure Algorithm

End point title	Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 Open-Label as Defined by Missing = Failure Algorithm
-----------------	--

End point description:

The percentage of participants with HIV-1 RNA < 50 copies/mL was analyzed using Missing = Failure for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set. All missing data was treated as HIV-1 RNA ≥ 50 copies/mL. The denominator for percentages was the number of participants in all B/F/TAF analysis set. Participants in the All B/F/TAF Analysis Set were analyzed. For the B/F/TAF group, Week 48 open-label time point refers to Week 192; for Missing = Failure analysis, it included all participants from the Randomized Phase.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, open-label Week 48

End point values	ABC/DTG/3TC to B/F/TAF	All B/F/TAF		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	254	314		
Units: percentage of participants				
number (confidence interval 95%)	83.5 (78.3 to 87.8)	74.8 (69.7 to 79.5)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 Open-Label as Defined by Missing = Excluded Algorithm

End point title	Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 Open-Label as Defined by Missing = Excluded Algorithm
-----------------	---

End point description:

The percentage of participants with HIV-1 RNA < 50 copies/mL was analyzed using Missing = Excluded for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set. All missing data was excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation). The denominator for percentages at a visit was the number of participants in the all B/F/TAF analysis set with non-missing HIV-1 RNA value at that visit. Participants in the All B/F/TAF Analysis Set with available data were analyzed. For the B/F/TAF group, Week 96 open-label time point refers to Week 240; for Missing = Excluded analysis, it included available participants at that time point from the Randomized Phase.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, open-label Week 96

End point values	ABC/DTG/3TC to B/F/TAF	All B/F/TAF		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	218	213		
Units: percentage of participants				
number (confidence interval 95%)	99.5 (97.5 to 100)	97.7 (94.6 to 99.2)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 Open-Label as Defined by Missing = Failure Algorithm

End point title	Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 Open-Label as Defined by Missing = Failure Algorithm
End point description: The percentage of participants with HIV-1 RNA < 50 copies/mL was analyzed using Missing = Failure for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set. All missing data was treated as HIV-1 RNA ≥ 50 copies/ mL. The denominator for percentages was the number of participants in all B/F/TAF analysis set. Participants in the All B/F/TAF Analysis Set were analyzed. For the B/F/TAF group, Week 96 open-label time point refers to Week 240; for Missing = Failure analysis, it included all participants from the Randomized Phase.	
End point type	Secondary
End point timeframe: Baseline, open-label Week 96	

End point values	ABC/DTG/3TC to B/F/TAF	All B/F/TAF		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	254	314		
Units: percentage of participants				
number (confidence interval 95%)	85.4 (80.5 to 89.5)	66.2 (60.7 to 71.5)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in CD4+ Cell Count at Week 48 Open-Label

End point title	Change From Baseline in CD4+ Cell Count at Week 48 Open-Label
End point description: Participants in the All B/F/TAF Analysis Set with available data were analyzed. For the B/F/TAF group, Week 48 open-label time point refers to Week 192; for Change from Baseline in CD4 Cell Count analysis, it included the available participants at that time point from the Randomized Phase.	
End point type	Secondary
End point timeframe: Baseline, open-label Week 48	

End point values	ABC/DTG/3TC to B/F/TAF	All B/F/TAF		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	212	234		
Units: cells/μL				
arithmetic mean (standard deviation)	-4 (± 202.0)	330 (± 242.8)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in CD4+ Cell Count at Week 96 Open-Label

End point title	Change From Baseline in CD4+ Cell Count at Week 96 Open-Label
-----------------	---

End point description:

Participants in the All B/F/TAF Analysis Set with available data were analyzed. For the B/F/TAF group, Week 96 open-label time point refers to Week 240; for Change from Baseline in CD4 Cell Count analysis, it included the available participants at that time point from the Randomized Phase.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, open-label Week 96

End point values	ABC/DTG/3TC to B/F/TAF	All B/F/TAF		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	204	205		
Units: cell/ μ L				
arithmetic mean (standard deviation)	-15 (\pm 188.1)	339 (\pm 237.8)		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse Events: First dose date up to last dose date (maximum: 279 weeks) plus 30 days

All-Cause Mortality: Randomization date through last visit/follow up date (maximum duration: 282.4 weeks)

Adverse event reporting additional description:

Adverse Events: Safety Analysis Set included all participants who were randomized into the study and received at least 1 dose of study drug.

All-Cause Mortality: All Randomized Analysis Set included all participants randomized into the study.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	24.0
--------------------	------

Reporting groups

Reporting group title	B/F/TAF
-----------------------	---------

Reporting group description:

B/F/TAF (50/200/25 mg) FDC tablet + ABC/DTG/3TC placebo orally once daily for at least 144 weeks, without regard to food.

Reporting group title	ABC/DTG/3TC
-----------------------	-------------

Reporting group description:

ABC/DTG/3TC (600/50/300 mg) FDC tablet + B/F/TAF placebo orally once daily for at least 144 weeks, without regard to food.

Reporting group title	B/F/TAF to B/F/TAF
-----------------------	--------------------

Reporting group description:

After Week 144, participants continued to take their blinded study drug and attended visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants were given the option to receive OL B/F/TAF for 96 weeks. After the Week 96 OL Visit, participants in a country where B/F/TAF was not commercially available were given the option to continue OL B/F/TAF until the product became accessible through an access program or until Gilead elected to discontinue the study in that country, whichever occurred first.

Reporting group title	ABC/DTG/3TC to B/F/TAF
-----------------------	------------------------

Reporting group description:

After Week 144, participants continued to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants were given the option to receive OL B/F/TAF for 96 weeks. After the Week 96 OL Visit, participants in a country where B/F/TAF was not commercially available were given the option to continue OL B/F/TAF until the product became accessible through an access program or until Gilead elected to discontinue the study in that country, whichever occurred first.

Serious adverse events	B/F/TAF	ABC/DTG/3TC	B/F/TAF to B/F/TAF
Total subjects affected by serious adverse events			
subjects affected / exposed	44 / 314 (14.01%)	54 / 315 (17.14%)	19 / 252 (7.54%)
number of deaths (all causes)	2	1	2
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
High-grade B-cell lymphoma			

subjects affected / exposed	0 / 314 (0.00%)	2 / 315 (0.63%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaplastic large-cell lymphoma			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hodgkin's disease			
subjects affected / exposed	1 / 314 (0.32%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lipoma			
subjects affected / exposed	1 / 314 (0.32%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostate cancer			
subjects affected / exposed	0 / 314 (0.00%)	0 / 315 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	1 / 314 (0.32%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral arterial occlusive ~ disease			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			

Abortion induced			
subjects affected / exposed	0 / 314 (0.00%)	0 / 315 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
subjects affected / exposed	1 / 314 (0.32%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	2 / 314 (0.64%)	2 / 315 (0.63%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	1 / 314 (0.32%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest discomfort			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	0 / 314 (0.00%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug withdrawal syndrome			
subjects affected / exposed	0 / 314 (0.00%)	0 / 315 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Social circumstances			
Alcohol use			

subjects affected / exposed	0 / 314 (0.00%)	0 / 315 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Endometrial thickening			
subjects affected / exposed	0 / 314 (0.00%)	0 / 315 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Penile necrosis			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Testicular mass			
subjects affected / exposed	1 / 314 (0.32%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Testicular pain			
subjects affected / exposed	1 / 314 (0.32%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine polyp			
subjects affected / exposed	0 / 314 (0.00%)	0 / 315 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Pulmonary embolism			
subjects affected / exposed	1 / 314 (0.32%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory failure			
subjects affected / exposed	0 / 314 (0.00%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Dyspnoea			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nasal turbinate hypertrophy			
subjects affected / exposed	1 / 314 (0.32%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary oedema			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Suicidal ideation			
subjects affected / exposed	3 / 314 (0.96%)	3 / 315 (0.95%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 3	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt			
subjects affected / exposed	2 / 314 (0.64%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression			
subjects affected / exposed	0 / 314 (0.00%)	2 / 315 (0.63%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Major depression			
subjects affected / exposed	3 / 314 (0.96%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Borderline personality disorder			

subjects affected / exposed	1 / 314 (0.32%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental disorder			
subjects affected / exposed	1 / 314 (0.32%)	0 / 315 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychotic disorder			
subjects affected / exposed	1 / 314 (0.32%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anxiety			
subjects affected / exposed	1 / 314 (0.32%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bipolar I disorder			
subjects affected / exposed	1 / 314 (0.32%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delirium tremens			
subjects affected / exposed	1 / 314 (0.32%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug dependence			
subjects affected / exposed	0 / 314 (0.00%)	0 / 315 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hallucination, tactile			
subjects affected / exposed	0 / 314 (0.00%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intentional self-injury			

subjects affected / exposed	1 / 314 (0.32%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Schizophrenia			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Anticoagulation drug level above ~ therapeutic			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric evaluation			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
White blood cell count increased			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Road traffic accident			
subjects affected / exposed	0 / 314 (0.00%)	3 / 315 (0.95%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxicity to various agents			
subjects affected / exposed	0 / 314 (0.00%)	2 / 315 (0.63%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Limb injury			
subjects affected / exposed	1 / 314 (0.32%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Overdose			
subjects affected / exposed	2 / 314 (0.64%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Accidental overdose			
subjects affected / exposed	1 / 314 (0.32%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Acetabulum fracture			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Alcohol poisoning			
subjects affected / exposed	1 / 314 (0.32%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fibula fracture			
subjects affected / exposed	0 / 314 (0.00%)	0 / 315 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint dislocation			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower limb fracture			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative ileus			

subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary contusion			
subjects affected / exposed	0 / 314 (0.00%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal fracture			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stab wound			
subjects affected / exposed	0 / 314 (0.00%)	0 / 315 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture			
subjects affected / exposed	0 / 314 (0.00%)	0 / 315 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Traumatic fracture			
subjects affected / exposed	0 / 314 (0.00%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	1 / 314 (0.32%)	0 / 315 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure acute			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			

subjects affected / exposed	0 / 314 (0.00%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular tachycardia			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Seizure			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bell's palsy			
subjects affected / exposed	0 / 314 (0.00%)	0 / 315 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Generalised tonic-clonic seizure			
subjects affected / exposed	1 / 314 (0.32%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoaesthesia			
subjects affected / exposed	1 / 314 (0.32%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			

subjects affected / exposed	0 / 314 (0.00%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 314 (0.64%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia of chronic disease			
subjects affected / exposed	1 / 314 (0.32%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Middle ear adhesions			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vertigo			
subjects affected / exposed	1 / 314 (0.32%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Blindness transient			
subjects affected / exposed	1 / 314 (0.32%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Pancreatitis acute			

subjects affected / exposed	1 / 314 (0.32%)	2 / 315 (0.63%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematemesis			
subjects affected / exposed	2 / 314 (0.64%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal hernia			
subjects affected / exposed	1 / 314 (0.32%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal incarcerated hernia			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric varices haemorrhage			

subjects affected / exposed	0 / 314 (0.00%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematochezia			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoids thrombosed			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal food impaction			
subjects affected / exposed	1 / 314 (0.32%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Steatorrhea			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			

subjects affected / exposed	0 / 314 (0.00%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	0 / 314 (0.00%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic cytolysis			
subjects affected / exposed	1 / 314 (0.32%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis acute			
subjects affected / exposed	1 / 314 (0.32%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic kidney disease			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic nephropathy			
subjects affected / exposed	0 / 314 (0.00%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
End stage renal disease			

subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			
subjects affected / exposed	0 / 314 (0.00%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Goitre			
subjects affected / exposed	1 / 314 (0.32%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Gouty arthritis			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc protrusion			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscular weakness			
subjects affected / exposed	1 / 314 (0.32%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neck pain			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Infections and infestations Appendicitis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	3 / 314 (0.96%) 0 / 3 0 / 0	2 / 315 (0.63%) 0 / 2 0 / 0	0 / 252 (0.00%) 0 / 0 0 / 0
Abscess limb subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	2 / 314 (0.64%) 0 / 2 0 / 0	2 / 315 (0.63%) 0 / 2 0 / 0	0 / 252 (0.00%) 0 / 0 0 / 0
Pneumonia subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	2 / 314 (0.64%) 0 / 2 0 / 0	1 / 315 (0.32%) 0 / 1 0 / 0	0 / 252 (0.00%) 0 / 0 0 / 0
Cellulitis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 314 (0.32%) 0 / 1 0 / 0	0 / 315 (0.00%) 0 / 0 0 / 0	0 / 252 (0.00%) 0 / 0 0 / 0
Neurosyphilis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 314 (0.32%) 0 / 1 0 / 0	2 / 315 (0.63%) 0 / 2 0 / 0	0 / 252 (0.00%) 0 / 0 0 / 0
Anal abscess subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 314 (0.00%) 0 / 0 0 / 0	1 / 315 (0.32%) 0 / 1 0 / 0	1 / 252 (0.40%) 0 / 1 0 / 0
Appendicitis perforated subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	2 / 314 (0.64%) 0 / 2 0 / 0	0 / 315 (0.00%) 0 / 0 0 / 0	0 / 252 (0.00%) 0 / 0 0 / 0
Covid-19 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 314 (0.00%) 0 / 0 0 / 0	0 / 315 (0.00%) 0 / 0 0 / 0	2 / 252 (0.79%) 0 / 2 0 / 1
Gastroenteritis			

subjects affected / exposed	0 / 314 (0.00%)	2 / 315 (0.63%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis A			
subjects affected / exposed	0 / 314 (0.00%)	2 / 315 (0.63%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Perirectal abscess			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 314 (0.00%)	2 / 315 (0.63%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal wall abscess			
subjects affected / exposed	1 / 314 (0.32%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast abscess			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			

subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Complicated appendicitis			
subjects affected / exposed	0 / 314 (0.00%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Covid-19 pneumonia			
subjects affected / exposed	0 / 314 (0.00%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterobacter sepsis			
subjects affected / exposed	0 / 314 (0.00%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fungaemia			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gonococcal infection			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gonorrhoea			

subjects affected / exposed	1 / 314 (0.32%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Groin abscess			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injection site cellulitis			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Kidney infection			
subjects affected / exposed	0 / 314 (0.00%)	0 / 315 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Localised infection			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mastoiditis			
subjects affected / exposed	1 / 314 (0.32%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis cryptococcal			
subjects affected / exposed	1 / 314 (0.32%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mycobacterium avium complex ~ infection			

subjects affected / exposed	1 / 314 (0.32%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ophthalmic herpes zoster			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Orchitis			
subjects affected / exposed	1 / 314 (0.32%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngeal abscess			
subjects affected / exposed	1 / 314 (0.32%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia bacterial			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia legionella			
subjects affected / exposed	0 / 314 (0.00%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia pneumococcal			
subjects affected / exposed	0 / 314 (0.00%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 314 (0.00%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Soft tissue infection			

subjects affected / exposed	1 / 314 (0.32%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tracheobronchitis			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	0 / 314 (0.00%)	0 / 315 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection			
subjects affected / exposed	0 / 314 (0.00%)	0 / 315 (0.00%)	1 / 252 (0.40%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetes mellitus inadequate control			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic ketoacidosis			
subjects affected / exposed	1 / 314 (0.32%)	0 / 315 (0.00%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	0 / 314 (0.00%)	1 / 315 (0.32%)	0 / 252 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	ABC/DTG/3TC to		
-------------------------------	----------------	--	--

	B/F/TAF		
Total subjects affected by serious adverse events			
subjects affected / exposed	19 / 254 (7.48%)		
number of deaths (all causes)	2		
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
High-grade B-cell lymphoma			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Anaplastic large-cell lymphoma			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hodgkin's disease			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lipoma			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Prostate cancer			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypotension			

subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peripheral arterial occlusive ~ disease			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Surgical and medical procedures			
Abortion induced			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	1 / 254 (0.39%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pyrexia			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Chest discomfort			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Death			

subjects affected / exposed	1 / 254 (0.39%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Drug withdrawal syndrome			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Social circumstances			
Alcohol use			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Reproductive system and breast disorders			
Endometrial thickening			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Penile necrosis			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Testicular mass			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Testicular pain			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Uterine polyp			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Respiratory, thoracic and mediastinal disorders			
Pulmonary embolism			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Acute respiratory failure			
subjects affected / exposed	1 / 254 (0.39%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Dyspnoea			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nasal turbinate hypertrophy			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary oedema			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory failure			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Suicidal ideation			
subjects affected / exposed	1 / 254 (0.39%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Suicide attempt			
subjects affected / exposed	1 / 254 (0.39%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Depression				
subjects affected / exposed	0 / 254 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Major depression				
subjects affected / exposed	0 / 254 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Borderline personality disorder				
subjects affected / exposed	0 / 254 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Mental disorder				
subjects affected / exposed	0 / 254 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Psychotic disorder				
subjects affected / exposed	0 / 254 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Anxiety				
subjects affected / exposed	0 / 254 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bipolar I disorder				
subjects affected / exposed	0 / 254 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Delirium tremens				
subjects affected / exposed	0 / 254 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Drug dependence				

subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hallucination, tactile			
subjects affected / exposed	1 / 254 (0.39%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Intentional self-injury			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Schizophrenia			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Investigations			
Anticoagulation drug level above ~ therapeutic			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychiatric evaluation			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
White blood cell count increased			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Road traffic accident			
subjects affected / exposed	1 / 254 (0.39%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

<p>Toxicity to various agents</p> <p>subjects affected / exposed</p> <p>0 / 254 (0.00%)</p> <p>occurrences causally related to treatment / all</p> <p>0 / 0</p> <p>deaths causally related to treatment / all</p> <p>0 / 0</p>				
<p>Limb injury</p> <p>subjects affected / exposed</p> <p>0 / 254 (0.00%)</p> <p>occurrences causally related to treatment / all</p> <p>0 / 0</p> <p>deaths causally related to treatment / all</p> <p>0 / 0</p>				
<p>Overdose</p> <p>subjects affected / exposed</p> <p>0 / 254 (0.00%)</p> <p>occurrences causally related to treatment / all</p> <p>0 / 0</p> <p>deaths causally related to treatment / all</p> <p>0 / 0</p>				
<p>Accidental overdose</p> <p>subjects affected / exposed</p> <p>0 / 254 (0.00%)</p> <p>occurrences causally related to treatment / all</p> <p>0 / 0</p> <p>deaths causally related to treatment / all</p> <p>0 / 0</p>				
<p>Acetabulum fracture</p> <p>subjects affected / exposed</p> <p>0 / 254 (0.00%)</p> <p>occurrences causally related to treatment / all</p> <p>0 / 0</p> <p>deaths causally related to treatment / all</p> <p>0 / 0</p>				
<p>Alcohol poisoning</p> <p>subjects affected / exposed</p> <p>0 / 254 (0.00%)</p> <p>occurrences causally related to treatment / all</p> <p>0 / 0</p> <p>deaths causally related to treatment / all</p> <p>0 / 0</p>				
<p>Femur fracture</p> <p>subjects affected / exposed</p> <p>0 / 254 (0.00%)</p> <p>occurrences causally related to treatment / all</p> <p>0 / 0</p> <p>deaths causally related to treatment / all</p> <p>0 / 0</p>				
<p>Fibula fracture</p> <p>subjects affected / exposed</p> <p>0 / 254 (0.00%)</p> <p>occurrences causally related to treatment / all</p> <p>0 / 0</p> <p>deaths causally related to treatment / all</p> <p>0 / 0</p>				
<p>Joint dislocation</p>				

subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lower limb fracture			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Postoperative ileus			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary contusion			
subjects affected / exposed	1 / 254 (0.39%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Spinal fracture			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Stab wound			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tibia fracture			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Traumatic fracture			
subjects affected / exposed	1 / 254 (0.39%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Atrial fibrillation			

subjects affected / exposed	1 / 254 (0.39%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac failure acute			
subjects affected / exposed	1 / 254 (0.39%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Acute myocardial infarction			
subjects affected / exposed	1 / 254 (0.39%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Myocardial infarction			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ventricular tachycardia			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Seizure			
subjects affected / exposed	1 / 254 (0.39%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Bell's palsy			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Generalised tonic-clonic seizure			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Headache			

subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypoaesthesia			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ischaemic stroke			
subjects affected / exposed	1 / 254 (0.39%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 254 (0.39%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Anaemia of chronic disease			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Febrile neutropenia			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ear and labyrinth disorders			
Middle ear adhesions			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vertigo			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Eye disorders			

Blindness transient			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Pancreatitis acute			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abdominal pain			
subjects affected / exposed	1 / 254 (0.39%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Diarrhoea			
subjects affected / exposed	1 / 254 (0.39%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal haemorrhage			
subjects affected / exposed	1 / 254 (0.39%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Haematemesis			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abdominal hernia			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abdominal incarcerated hernia			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Constipation			

subjects affected / exposed	0 / 254 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastric varices haemorrhage				
subjects affected / exposed	1 / 254 (0.39%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Haematochezia				
subjects affected / exposed	0 / 254 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Haemorrhoids thrombosed				
subjects affected / exposed	0 / 254 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lower gastrointestinal haemorrhage				
subjects affected / exposed	0 / 254 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Nausea				
subjects affected / exposed	0 / 254 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Oesophageal food impaction				
subjects affected / exposed	0 / 254 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Small intestinal obstruction				
subjects affected / exposed	0 / 254 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Steatorrhoea				

subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Upper gastrointestinal haemorrhage			
subjects affected / exposed	1 / 254 (0.39%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Vomiting			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	1 / 254 (0.39%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatic cytolysis			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatitis acute			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	2 / 254 (0.79%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Chronic kidney disease			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diabetic nephropathy			

subjects affected / exposed	1 / 254 (0.39%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
End stage renal disease			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nephrolithiasis			
subjects affected / exposed	1 / 254 (0.39%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal failure			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Endocrine disorders			
Goitre			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Gouty arthritis			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intervertebral disc protrusion			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Muscular weakness			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Neck pain			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abscess limb			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia			
subjects affected / exposed	1 / 254 (0.39%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cellulitis			
subjects affected / exposed	2 / 254 (0.79%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Neurosyphilis			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Anal abscess			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Appendicitis perforated			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Covid-19			

subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatitis A			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Osteomyelitis			
subjects affected / exposed	1 / 254 (0.39%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Perirectal abscess			
subjects affected / exposed	1 / 254 (0.39%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Sepsis			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abdominal wall abscess			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bacteraemia			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Breast abscess			

subjects affected / exposed	0 / 254 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bronchitis				
subjects affected / exposed	0 / 254 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Complicated appendicitis				
subjects affected / exposed	1 / 254 (0.39%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Covid-19 pneumonia				
subjects affected / exposed	1 / 254 (0.39%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Diverticulitis				
subjects affected / exposed	0 / 254 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Enterobacter sepsis				
subjects affected / exposed	1 / 254 (0.39%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Fungaemia				
subjects affected / exposed	0 / 254 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis viral				
subjects affected / exposed	0 / 254 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gonococcal infection				

subjects affected / exposed	0 / 254 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gonorrhoea				
subjects affected / exposed	0 / 254 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Groin abscess				
subjects affected / exposed	0 / 254 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Influenza				
subjects affected / exposed	0 / 254 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Injection site cellulitis				
subjects affected / exposed	0 / 254 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Kidney infection				
subjects affected / exposed	0 / 254 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Localised infection				
subjects affected / exposed	0 / 254 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Mastoiditis				
subjects affected / exposed	0 / 254 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Meningitis cryptococcal				

subjects affected / exposed	0 / 254 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Mycobacterium avium complex ~ infection				
subjects affected / exposed	0 / 254 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ophthalmic herpes zoster				
subjects affected / exposed	0 / 254 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Orchitis				
subjects affected / exposed	0 / 254 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pharyngeal abscess				
subjects affected / exposed	0 / 254 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia bacterial				
subjects affected / exposed	0 / 254 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia legionella				
subjects affected / exposed	1 / 254 (0.39%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pneumonia pneumococcal				
subjects affected / exposed	1 / 254 (0.39%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Septic shock				

subjects affected / exposed	1 / 254 (0.39%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Soft tissue infection			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tracheobronchitis			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Viral infection			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Wound infection			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diabetes mellitus inadequate control			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diabetic ketoacidosis			
subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyperkalaemia			

subjects affected / exposed	0 / 254 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	B/F/TAF	ABC/DTG/3TC	B/F/TAF to B/F/TAF
Total subjects affected by non-serious adverse events			
subjects affected / exposed	262 / 314 (83.44%)	276 / 315 (87.62%)	152 / 252 (60.32%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Anogenital warts			
subjects affected / exposed	12 / 314 (3.82%)	19 / 315 (6.03%)	6 / 252 (2.38%)
occurrences (all)	13	20	6
Vascular disorders			
Hypertension			
subjects affected / exposed	24 / 314 (7.64%)	16 / 315 (5.08%)	8 / 252 (3.17%)
occurrences (all)	24	16	8
Nervous system disorders			
Headache			
subjects affected / exposed	44 / 314 (14.01%)	56 / 315 (17.78%)	8 / 252 (3.17%)
occurrences (all)	63	70	8
Dizziness			
subjects affected / exposed	10 / 314 (3.18%)	19 / 315 (6.03%)	2 / 252 (0.79%)
occurrences (all)	14	19	2
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	35 / 314 (11.15%)	41 / 315 (13.02%)	7 / 252 (2.78%)
occurrences (all)	37	48	7
Pyrexia			
subjects affected / exposed	15 / 314 (4.78%)	19 / 315 (6.03%)	8 / 252 (3.17%)
occurrences (all)	18	22	8
Immune system disorders			
Seasonal allergy			
subjects affected / exposed	7 / 314 (2.23%)	16 / 315 (5.08%)	3 / 252 (1.19%)
occurrences (all)	7	18	3
Gastrointestinal disorders			

Nausea			
subjects affected / exposed	40 / 314 (12.74%)	77 / 315 (24.44%)	8 / 252 (3.17%)
occurrences (all)	44	94	8
Diarrhoea			
subjects affected / exposed	54 / 314 (17.20%)	57 / 315 (18.10%)	6 / 252 (2.38%)
occurrences (all)	61	79	6
Abdominal pain			
subjects affected / exposed	18 / 314 (5.73%)	23 / 315 (7.30%)	5 / 252 (1.98%)
occurrences (all)	18	25	6
Vomiting			
subjects affected / exposed	18 / 314 (5.73%)	24 / 315 (7.62%)	3 / 252 (1.19%)
occurrences (all)	20	27	3
Constipation			
subjects affected / exposed	15 / 314 (4.78%)	17 / 315 (5.40%)	2 / 252 (0.79%)
occurrences (all)	15	17	2
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	34 / 314 (10.83%)	22 / 315 (6.98%)	13 / 252 (5.16%)
occurrences (all)	42	25	13
Oropharyngeal pain			
subjects affected / exposed	22 / 314 (7.01%)	35 / 315 (11.11%)	13 / 252 (5.16%)
occurrences (all)	25	42	15
Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	30 / 314 (9.55%)	32 / 315 (10.16%)	10 / 252 (3.97%)
occurrences (all)	34	37	10
Psychiatric disorders			
Anxiety			
subjects affected / exposed	31 / 314 (9.87%)	21 / 315 (6.67%)	11 / 252 (4.37%)
occurrences (all)	31	22	12
Insomnia			
subjects affected / exposed	27 / 314 (8.60%)	35 / 315 (11.11%)	8 / 252 (3.17%)
occurrences (all)	29	36	8
Depression			
subjects affected / exposed	19 / 314 (6.05%)	27 / 315 (8.57%)	4 / 252 (1.59%)
occurrences (all)	19	27	4

Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	35 / 314 (11.15%)	43 / 315 (13.65%)	15 / 252 (5.95%)
occurrences (all)	38	48	15
Arthralgia			
subjects affected / exposed	36 / 314 (11.46%)	41 / 315 (13.02%)	13 / 252 (5.16%)
occurrences (all)	40	46	13
Pain in extremity			
subjects affected / exposed	18 / 314 (5.73%)	13 / 315 (4.13%)	9 / 252 (3.57%)
occurrences (all)	20	14	11
Infections and infestations			
Upper respiratory tract infection			
subjects affected / exposed	46 / 314 (14.65%)	61 / 315 (19.37%)	16 / 252 (6.35%)
occurrences (all)	64	91	17
Syphilis			
subjects affected / exposed	43 / 314 (13.69%)	51 / 315 (16.19%)	22 / 252 (8.73%)
occurrences (all)	50	63	25
Nasopharyngitis			
subjects affected / exposed	41 / 314 (13.06%)	52 / 315 (16.51%)	18 / 252 (7.14%)
occurrences (all)	63	84	22
Anal chlamydia infection			
subjects affected / exposed	16 / 314 (5.10%)	29 / 315 (9.21%)	6 / 252 (2.38%)
occurrences (all)	18	35	8
Proctitis gonococcal			
subjects affected / exposed	17 / 314 (5.41%)	21 / 315 (6.67%)	9 / 252 (3.57%)
occurrences (all)	20	26	12
Bronchitis			
subjects affected / exposed	20 / 314 (6.37%)	30 / 315 (9.52%)	3 / 252 (1.19%)
occurrences (all)	20	37	3
Gonorrhoea			
subjects affected / exposed	22 / 314 (7.01%)	21 / 315 (6.67%)	5 / 252 (1.98%)
occurrences (all)	24	25	5
Chlamydial infection			
subjects affected / exposed	23 / 314 (7.32%)	13 / 315 (4.13%)	8 / 252 (3.17%)
occurrences (all)	25	16	8
Gastroenteritis			

subjects affected / exposed	17 / 314 (5.41%)	21 / 315 (6.67%)	6 / 252 (2.38%)
occurrences (all)	19	25	7
Influenza			
subjects affected / exposed	22 / 314 (7.01%)	16 / 315 (5.08%)	4 / 252 (1.59%)
occurrences (all)	22	17	5
Pharyngitis			
subjects affected / exposed	17 / 314 (5.41%)	23 / 315 (7.30%)	6 / 252 (2.38%)
occurrences (all)	19	25	6
Sinusitis			
subjects affected / exposed	15 / 314 (4.78%)	23 / 315 (7.30%)	3 / 252 (1.19%)
occurrences (all)	18	28	3
Covid-19			
subjects affected / exposed	0 / 314 (0.00%)	0 / 315 (0.00%)	20 / 252 (7.94%)
occurrences (all)	0	0	20

Non-serious adverse events	ABC/DTG/3TC to B/F/TAF		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	153 / 254 (60.24%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Anogenital warts			
subjects affected / exposed	3 / 254 (1.18%)		
occurrences (all)	3		
Vascular disorders			
Hypertension			
subjects affected / exposed	9 / 254 (3.54%)		
occurrences (all)	9		
Nervous system disorders			
Headache			
subjects affected / exposed	9 / 254 (3.54%)		
occurrences (all)	10		
Dizziness			
subjects affected / exposed	2 / 254 (0.79%)		
occurrences (all)	2		
General disorders and administration site conditions			
Fatigue			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Pyrexia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>11 / 254 (4.33%)</p> <p>13</p> <p>8 / 254 (3.15%)</p> <p>9</p>		
<p>Immune system disorders</p> <p>Seasonal allergy</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>5 / 254 (1.97%)</p> <p>6</p>		
<p>Gastrointestinal disorders</p> <p>Nausea</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Diarrhoea</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Abdominal pain</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Vomiting</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Constipation</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>7 / 254 (2.76%)</p> <p>8</p> <p>13 / 254 (5.12%)</p> <p>13</p> <p>6 / 254 (2.36%)</p> <p>7</p> <p>7 / 254 (2.76%)</p> <p>8</p> <p>6 / 254 (2.36%)</p> <p>7</p>		
<p>Respiratory, thoracic and mediastinal disorders</p> <p>Cough</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Oropharyngeal pain</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>9 / 254 (3.54%)</p> <p>10</p> <p>6 / 254 (2.36%)</p> <p>7</p>		
<p>Skin and subcutaneous tissue disorders</p> <p>Rash</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>6 / 254 (2.36%)</p> <p>6</p>		

Psychiatric disorders Anxiety subjects affected / exposed occurrences (all) Insomnia subjects affected / exposed occurrences (all) Depression subjects affected / exposed occurrences (all)	12 / 254 (4.72%) 12 5 / 254 (1.97%) 5 12 / 254 (4.72%) 12		
Musculoskeletal and connective tissue disorders Back pain subjects affected / exposed occurrences (all) Arthralgia subjects affected / exposed occurrences (all) Pain in extremity subjects affected / exposed occurrences (all)	15 / 254 (5.91%) 15 12 / 254 (4.72%) 12 12 / 254 (4.72%) 12		
Infections and infestations Upper respiratory tract infection subjects affected / exposed occurrences (all) Syphilis subjects affected / exposed occurrences (all) Nasopharyngitis subjects affected / exposed occurrences (all) Anal chlamydia infection subjects affected / exposed occurrences (all) Proctitis gonococcal subjects affected / exposed occurrences (all)	19 / 254 (7.48%) 23 22 / 254 (8.66%) 27 14 / 254 (5.51%) 18 11 / 254 (4.33%) 13 13 / 254 (5.12%) 18		

Bronchitis			
subjects affected / exposed	2 / 254 (0.79%)		
occurrences (all)	2		
Gonorrhoea			
subjects affected / exposed	5 / 254 (1.97%)		
occurrences (all)	5		
Chlamydial infection			
subjects affected / exposed	8 / 254 (3.15%)		
occurrences (all)	9		
Gastroenteritis			
subjects affected / exposed	8 / 254 (3.15%)		
occurrences (all)	8		
Influenza			
subjects affected / exposed	9 / 254 (3.54%)		
occurrences (all)	9		
Pharyngitis			
subjects affected / exposed	5 / 254 (1.97%)		
occurrences (all)	5		
Sinusitis			
subjects affected / exposed	4 / 254 (1.57%)		
occurrences (all)	4		
Covid-19			
subjects affected / exposed	23 / 254 (9.06%)		
occurrences (all)	23		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
19 February 2016	<ul style="list-style-type: none">• Modified inclusion criteria to allow for local laboratory results for the screening genotype report and human leukocyte antigen (HLA)-B*5701 results• Clarified criteria for discontinuation of study treatment and for management of laboratory toxicity• Included guidance for management of potential hepatobiliary toxicity
19 October 2016	<ul style="list-style-type: none">• Extended duration of blinded phase from 96 weeks of treatment to 144 weeks of treatment• Revised secondary objectives and endpoints to include Week 144• Added open-label (OL) rollover extension and treatment assessments for participants who receive OL Biktarvy (BVY)• Revised prior and concomitant medications• Added hepatitis B virus (HBV) and hepatitis C virus (HCV) serology testing at Week 48 and every 48 weeks after Week 48• Revised Gilead reporting requirements to clarify that, in addition to using the reference safety information in the investigator's brochure and relevant local label as applicable, Gilead may also use the EU summary of product characteristics for the assessment of expectedness of serious adverse events (SAEs) for ABC/DTG/3TC• Revised the definition of special situations• Added peripheral blood mononuclear cell (PBMC) collection at Week 132 in the PBMC substudy• Revised biomarker analysis
06 May 2019	<ul style="list-style-type: none">• Extended the duration of the OL extension phase of the study from up to 48 weeks to 96 weeks to allow collection of longer term safety and efficacy data.• Revised Secondary Objectives and End Points• Revised Duration of Treatment• Revised Procedures for Breaking Treatment Codes• Added Prior and Concomitant Medications Table for GS-9883/F/TAF Open Label Extension• Revised end of blinded treatment visit• Revised Treatment Assessments (Open-Label Rollover Extension)• Revised Bone Safety Evaluations and Bone Mineral Density Evaluations• Revised Markers of Renal Tubular Function• Revised participant with HIV-1 ribonucleic acid (RNA) ≥ 50 copies/mL instructions to include Week 96 OL• Revised from Gilead Drug Safety and Public Health (DSPH) to Gilead Pharmacovigilance and Epidemiology (PVE) throughout the protocol amendment• Revised instructions for reporting special situations• Added All GS-9883/F/TAF Analysis Set• Added Efficacy Analyses for All GS-9883/F/TAF Analysis• Revised Safety Analysis• Revised Analysis Schedule• Revised Appendix 2 footnotes• Revised Appendix 3 to include OL visits through 96 weeks

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

Online references

<http://www.ncbi.nlm.nih.gov/pubmed/28867497>

<http://www.ncbi.nlm.nih.gov/pubmed/29956087>

<http://www.ncbi.nlm.nih.gov/pubmed/30803969>

<http://www.ncbi.nlm.nih.gov/pubmed/31068270>

<http://www.ncbi.nlm.nih.gov/pubmed/32504574>

<http://www.ncbi.nlm.nih.gov/pubmed/33880558>